Developer and seller of microfluidic systems, Fluidigm Corp (FLDM), recently announced a new workflow that will enable high throughput single-cell mRNA sequencing at a lower cost.
The new workflow has been primarily designed to allow researchers to profile substantially larger numbers of individual cells. Notably, the full commercial version is expected to be accessible in the first half of 2015.
The improvement in integrated fluid circuit (IFC) design will help capture and process up to 750 single cells per run. Workflow efficiency partnered with data density per sequencing run is expected to cut down costs for cell preparation and sequencing.
The Fluidigm C1 Single-Cell Auto Prep System is based on the company's inventive microfluidic technology which aids researchers in isolating, processing and profiling individual cells. The high throughput single-cell mRNA sequencing workflow will be the latest addition enabled on the C1 system.
We believe that Fluidigm’s innovative product pipeline is a key growth catalyst. The company has strong growth opportunities across both production genomics and single-cell genomics applications.
Fluidigm recently started an early access program for its upcoming Juno genotyping machine. Per Endgadget, Juno uses a new improved circuit that can pre-amplify and analyze DNA in a single step, thereby saving significant amount of time for testers.
Juno needs a tiny amount of DNA to boot and shows results much faster (in three hours) compared to traditional devices (takes five to six hours), which will be a major attraction for doctors dealing with time-sensitive diseases.
The strong product pipeline is expected to drive top-line growth, as reflected by recent results. Instrument revenues soared 64% year over year in the third quarter, driven by increased sales of the C1 and BioMark HD systems, and higher contribution from the acquired CyTOF 2 system.
Most importantly, approximately 60% of the BioMark HD system sales were motivated by single-cell research. The introduction of the new workflow is expected to further enhance the growth prospects to this division going forward.
Moreover, we believe that Fluidigm’s expanding product portfolio will enhance its competitive position against the likes of Affymetrix (AFFX), Illumina (ILMN), and Thermo Fisher Scientific (TMO).
Currently, Fluidigm Corp carries a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment